Michael A Lea1, Jacob Pourat1, Rupali Patel1, Charles desBordes1. 1. Michael A Lea, Jacob Pourat, Rupali Patel, Charles desBordes, Department of Biochemistry and Molecular Biology, New Jersey Medical School, Rutgers University, Newark, NJ 07103, United States.
Abstract
AIM: To determine if other molecules reported to modulate AMP-dependent protein kinase (AMPK) activity would have effects resembling those of metformin and phenformin on colon cancer cell proliferation and metabolism. METHODS: Studies were performed with four human colon cancer cell lines, Caco-2, HCT116, HT29 and SW1116. The compounds that were studied included A-769662, 5-aminoimidazole-4-carboxamide-1-ribofuranoside, butyrate, (-)-epigallocatechin gallate (EGCG), KU-55933, quercetin, resveratrol and salicylates. The parameters that were measured were cell proliferation and viability, glucose uptake, lactate production and acidification of the incubation medium. RESULTS: Investigations with several molecules that have been reported to be associated with AMPK activation (A-769662, 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside, EGCG, KU-55933, quercetin, resveratrol and salicylates) or AMPK inhibition (compound C) failed to reveal increased medium acidification and increased glucose uptake in colon cancer cells as previously established with metformin and phenformin. The only exception was 5-aminosalicylic acid with which there were apparently lower glucose levels in the medium after incubation for 72 h. Further study in the absence of cells revealed that the effect was an artifact due to inhibition of the enzyme-linked glucose assay. The compounds were studied at concentrations that inhibited cell proliferation. CONCLUSION: It was concluded that treatment with several agents that can affect AMPK activity resulted in the inhibition of the proliferation of colon cancer cells under conditions in which glucose metabolism is not enhanced, in contrast to the effect of biguanides.
AIM: To determine if other molecules reported to modulate AMP-dependent protein kinase (AMPK) activity would have effects resembling those of metformin and phenformin on colon cancer cell proliferation and metabolism. METHODS: Studies were performed with four humancolon cancer cell lines, Caco-2, HCT116, HT29 and SW1116. The compounds that were studied included A-769662, 5-aminoimidazole-4-carboxamide-1-ribofuranoside, butyrate, (-)-epigallocatechin gallate (EGCG), KU-55933, quercetin, resveratrol and salicylates. The parameters that were measured were cell proliferation and viability, glucose uptake, lactate production and acidification of the incubation medium. RESULTS: Investigations with several molecules that have been reported to be associated with AMPK activation (A-769662, 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside, EGCG, KU-55933, quercetin, resveratrol and salicylates) or AMPK inhibition (compound C) failed to reveal increased medium acidification and increased glucose uptake in colon cancer cells as previously established with metformin and phenformin. The only exception was 5-aminosalicylic acid with which there were apparently lower glucose levels in the medium after incubation for 72 h. Further study in the absence of cells revealed that the effect was an artifact due to inhibition of the enzyme-linked glucose assay. The compounds were studied at concentrations that inhibited cell proliferation. CONCLUSION: It was concluded that treatment with several agents that can affect AMPK activity resulted in the inhibition of the proliferation of colon cancer cells under conditions in which glucose metabolism is not enhanced, in contrast to the effect of biguanides.
Entities:
Keywords:
AMP-dependent protein kinase; Colon cancer cells; Glucose metabolism; Proliferation
Authors: Johanna Munding; Wibke Ziebarth; Christian P Pox; Svetlana Ladigan; Markus Reiser; Dietrich Hüppe; Linda Brand; Wolff Schmiegel; Andrea Tannapfel; Anke C Reinacher-Schick Journal: Carcinogenesis Date: 2011-12-22 Impact factor: 4.944
Authors: Michael A Lea; Mehreen S Qureshi; Michael Buxhoeveden; Nicolette Gengel; Jessica Kleinschmit; Charles Desbordes Journal: Anticancer Res Date: 2013-02 Impact factor: 2.480
Authors: Farhat V N Din; Asta Valanciute; Vanessa P Houde; Daria Zibrova; Kevin A Green; Kei Sakamoto; Dario R Alessi; Malcolm G Dunlop Journal: Gastroenterology Date: 2012-03-06 Impact factor: 22.682
Authors: Mahvash Zakikhani; Miguel Bazile; Sina Hashemi; Shiva Javeshghani; Daina Avizonis; Julie St Pierre; Michael N Pollak Journal: PLoS One Date: 2012-11-21 Impact factor: 3.240
Authors: Si Hyoung Kim; Jun Goo Kang; Chul Sik Kim; Sung-Hee Ihm; Moon Gi Choi; Hyung Joon Yoo; Seong Jin Lee Journal: Endocrine Date: 2017-12-28 Impact factor: 3.633
Authors: M Michailidou; I N Melas; D E Messinis; S Klamt; L G Alexopoulos; F N Kolisis; H Loutrari Journal: CPT Pharmacometrics Syst Pharmacol Date: 2015-06-01